Start Date
May 25, 2018
Primary Completion Date
August 23, 2019
Study Completion Date
August 23, 2019
ETBX-011
Ad5 \[E1-, E2b-\]-CEA
GI-4000
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
haNK for infusion
NK-92 \[CD16.158V, ER IL-2\]
avelumab
Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Capecitabine
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Cyclophosphamide
anhydrous
5-Fluorouracil
5-FU; Fluorouracil
Leucovorin
Leucovorin calcium salt
nab-Paclitaxel
ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
Sorafenib
NEXAVAR® tablets, for oral use
SBRT
Stereotactic Body Radiation Therapy
Aldoxorubicin hydrochloride
HCl
ETBX-051
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061
Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
GI-6207
CEA yeast vaccine
GI-6301
Brachyury yeast vaccine
Cetuximab
ERBITUX® injection, for IV infusion)
N-803
Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
Chan Soon-Shiong Institute for Medicine, El Segundo
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY